Literature DB >> 23160902

Apelin is a marker of the progression of liver fibrosis and portal hypertension in patients with biliary atresia.

Wei Chen1, Takaharu Oue, Takehisa Ueno, Shuichiro Uehara, Noriaki Usui, Masahiro Fukuzawa.   

Abstract

PURPOSE: Apelin, the endogenous ligand of the angiotensin-like-receptor 1 (APJ), is thought to play an important role in liver disease. This study investigated the apelin expression in different stages of biliary atresia (BA) and investigated whether it is associated with the progression of disease.
METHODS: Liver tissues were obtained from patients at Kasai's procedure (KP), the follow-up stage after KP (Post-KP) and at liver transplantation (LT). Immunohistochemistry for apelin and its receptor APJ and real-time quantitative reverse transcriptase polymerase chain reaction for apelin mRNA expression were conducted.
RESULTS: The immunohistochemical study revealed that apelin was mainly localized in the perivenular areas of control liver tissue, and slightly detected in the hepatic stellate cells (HSC) and hepatocytes, whereas intense apelin immunoreactivity was detected in perivenular areas, HSC and hepatocytes of LT liver tissue. The apelin mRNA expression level was significantly higher in the LT group than in the KP and Post-KP group. Significant linear correlations were observed between the apelin mRNA level and liver fibrosis, serum total bilirubin and the grade of esophageal varices.
CONCLUSIONS: The hepatic apelin-APJ system is markedly activated in the progression of BA, especially in end-stage cirrhosis. The apelin expression level accurately reflects the severity of hepatic fibrosis and esophageal varices and therefore could be used as a prognostic factor in BA patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23160902     DOI: 10.1007/s00383-012-3210-7

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  20 in total

1.  Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo.

Authors:  Junji Ishida; Tatsuo Hashimoto; Yasumi Hashimoto; Shiro Nishiwaki; Taku Iguchi; Shuichi Harada; Takeshi Sugaya; Hitomi Matsuzaki; Rie Yamamoto; Naotaka Shiota; Hideki Okunishi; Minoru Kihara; Satoshi Umemura; Fumihiro Sugiyama; Ken-Ichi Yagami; Yoshitoshi Kasuya; Naoki Mochizuki; Akiyoshi Fukamizu
Journal:  J Biol Chem       Date:  2004-04-15       Impact factor: 5.157

2.  Overexpression of apelin receptor (APJ/AGTRL1) on hepatic stellate cells and sinusoidal angiogenesis in human cirrhotic liver.

Authors:  Hiroaki Yokomori; Masaya Oda; Kazunori Yoshimura; Sanae Machida; Fumihiko Kaneko; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2010-08-20       Impact factor: 7.527

3.  Long-term follow-up after surgery for patients with biliary atresia.

Authors:  R Ohi; M Nio; T Chiba; N Endo; M Goto; M Ibrahim
Journal:  J Pediatr Surg       Date:  1990-04       Impact factor: 2.545

4.  A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11.

Authors:  B F O'Dowd; M Heiber; A Chan; H H Heng; L C Tsui; J L Kennedy; X Shi; A Petronis; S R George; T Nguyen
Journal:  Gene       Date:  1993-12-22       Impact factor: 3.688

5.  Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver.

Authors:  Panayotis Lykavieris; Christophe Chardot; Maroun Sokhn; Frédéric Gauthier; Jacques Valayer; Olivier Bernard
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

6.  Apelin, a newly identified adipokine up-regulated by insulin and obesity.

Authors:  Jérémie Boucher; Bernard Masri; Danièle Daviaud; Stéphane Gesta; Charlotte Guigné; Anne Mazzucotelli; Isabelle Castan-Laurell; Ivan Tack; Bernard Knibiehler; Christian Carpéné; Yves Audigier; Jean-Sébastien Saulnier-Blache; Philippe Valet
Journal:  Endocrinology       Date:  2005-01-27       Impact factor: 4.736

7.  Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor.

Authors:  K Tatemoto; M Hosoya; Y Habata; R Fujii; T Kakegawa; M X Zou; Y Kawamata; S Fukusumi; S Hinuma; C Kitada; T Kurokawa; H Onda; M Fujino
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

8.  Apelin, a new enteric peptide: localization in the gastrointestinal tract, ontogeny, and stimulation of gastric cell proliferation and of cholecystokinin secretion.

Authors:  Guiyun Wang; Younes Anini; Wei Wei; Xiang Qi; Anne-Marie OCarroll; Tohru Mochizuki; Hui-Quin Wang; Mark R Hellmich; Ella W Englander; George H Greeley
Journal:  Endocrinology       Date:  2003-12-11       Impact factor: 4.736

9.  Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release.

Authors:  Nadia De Mota; Annabelle Reaux-Le Goazigo; Said El Messari; Nicolas Chartrel; Darren Roesch; Cynthia Dujardin; Claude Kordon; Hubert Vaudry; Françoise Moos; Catherine Llorens-Cortes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-01       Impact factor: 11.205

10.  Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility.

Authors:  István Szokodi; Pasi Tavi; Gábor Földes; Sari Voutilainen-Myllylä; Mika Ilves; Heikki Tokola; Sampsa Pikkarainen; Jarkko Piuhola; Jaana Rysä; Miklós Tóth; Heikki Ruskoaho
Journal:  Circ Res       Date:  2002-09-06       Impact factor: 17.367

View more
  8 in total

1.  Apelin Association with Hepatic Fibrosis and Esophageal Varices in Patients with Chronic Hepatitis C Virus.

Authors:  Lamyaa Abdellatif Soliman; Rania A Zayed; Dalia Omran; Fadwa Said; Samar Kamal Darweesh; Doaa Mohamed Ghaith; Rasha Eletreby; Mahmoud Salama Barakat; Mahmoud M Bendary; Doaa Zakaria Zaky; Eman Amer; Iman Rifaat Elmahgoub
Journal:  Am J Trop Med Hyg       Date:  2022-06-13       Impact factor: 3.707

2.  Chronic apelin treatment improves hepatic lipid metabolism in obese and insulin-resistant mice by an indirect mechanism.

Authors:  Chantal Bertrand; Jean-Philippe Pradère; Nancy Geoffre; Simon Deleruyelle; Bernard Masri; Jean Personnaz; Sophie Le Gonidec; Aurélie Batut; Katie Louche; Cédric Moro; Philippe Valet; Isabelle Castan-Laurell
Journal:  Endocrine       Date:  2018-02-01       Impact factor: 3.633

3.  Emerging role of adipokine apelin in hepatic remodelling and initiation of carcinogensis in chronic hepatitis C patients.

Authors:  Rola M Farid; Riham M Abu-Zeid; Ahmed El-Tawil
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

4.  Transplantation of Human Amniotic Membrane over the Liver Surface Reduces Hepatic Fibrosis in a Cholestatic Model in Young Rats.

Authors:  M Garrido; C Escobar; C Zamora; C Rejas; J Varas; C Córdova; C Papuzinski; M Párraga; S San Martín; S Montedonico
Journal:  Stem Cells Int       Date:  2018-02-25       Impact factor: 5.443

5.  Bile duct ligature in young rats: A revisited animal model for biliary atresia.

Authors:  Matias Garrido; Camila Escobar; Constanza Zamora; Carolina Rejas; Juan Varas; Mario Párraga; Sebastian San Martin; Sandra Montedónico
Journal:  Eur J Histochem       Date:  2017-09-13       Impact factor: 3.188

Review 6.  Portal hypertension as immune mediate disease.

Authors:  Sara Manti; Lucia Marseglia; Gabriella D'Angelo; Martina Filippelli; Caterina Cuppari; Eloisa Gitto; Claudio Romano; Teresa Arrigo; Carmelo Salpietro
Journal:  Hepat Mon       Date:  2014-06-07       Impact factor: 0.660

Review 7.  Apelin/APJ system: A key therapeutic target for liver disease.

Authors:  Shuang-Yu Lv; Binbin Cui; Wei-Dong Chen; Yan-Dong Wang
Journal:  Oncotarget       Date:  2017-12-01

8.  Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.

Authors:  Nicola E Owen; Duuamene Nyimanu; Rhoda E Kuc; Paul D Upton; Nicholas W Morrell; Graeme J Alexander; Janet J Maguire; Anthony P Davenport
Journal:  Peptides       Date:  2020-11-07       Impact factor: 3.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.